COMBINATION DRUG PRODUCTS FOR TREATING PATIENTS SUFFERING FROM ONE OR MORE MEDICAL CONDITIONS CAUSED BY CORONAVIRUS INFECTION, INCLUDING BY SARS-CoV-2, ITS ALPHA, BETA, DELTA, OR OMICRON VARIANTS AND SUB VARIANTS
Treatments for human subjects exposed to, potentially exposed to, infected by, or potentially infected by a coronavirus, such as SARS-CoV-2, its variants and sub variants are described, which are based on an administration of combination drug products having two or three active ingredients formulated with one or more pharmaceutically acceptable carriers. These patients (children, adults and the elderly) suffer from symptoms of COVID-19, and some may continue to suffer from its aftereffects many weeks or months after an infection, like long COVID, including neurological aymptoms such as brain fog and confusion. Physiological ailments may consist of symptoms such as fatigue, shortness of breath, difficulty breathing, joint and muscle aches, and the like. The two-component combination drug product comprises effective amounts of ANTABUSE (disulfiram) and PURINETHOL (mercaptopurine, 6-mercaptopurine, or 6-MP) or its prodrug IMURAN (azathioprine) or hydrates of these compounds. A three-component combination drug product adds, in addition to the foregoing active ingredients, an effective amount of dexamethasone or pharmacologically acceptable salts thereof..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 25. Jan. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
NAEGER DAVID M [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-01-25, Last update posted on www.tib.eu: 2024-02-28, Last updated: 2024-03-08 |
|---|
| Patentnummer: |
US2024024329 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA019157010 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA019157010 | ||
| 003 | DE-627 | ||
| 005 | 20240308101634.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240209s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA019157010 | ||
| 035 | |a (EPA)US2024024329 | ||
| 035 | |a (EPA)89578094 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a NAEGER DAVID M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COMBINATION DRUG PRODUCTS FOR TREATING PATIENTS SUFFERING FROM ONE OR MORE MEDICAL CONDITIONS CAUSED BY CORONAVIRUS INFECTION, INCLUDING BY SARS-CoV-2, ITS ALPHA, BETA, DELTA, OR OMICRON VARIANTS AND SUB VARIANTS |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-01-25, Last update posted on www.tib.eu: 2024-02-28, Last updated: 2024-03-08 | ||
| 520 | |a Treatments for human subjects exposed to, potentially exposed to, infected by, or potentially infected by a coronavirus, such as SARS-CoV-2, its variants and sub variants are described, which are based on an administration of combination drug products having two or three active ingredients formulated with one or more pharmaceutically acceptable carriers. These patients (children, adults and the elderly) suffer from symptoms of COVID-19, and some may continue to suffer from its aftereffects many weeks or months after an infection, like long COVID, including neurological aymptoms such as brain fog and confusion. Physiological ailments may consist of symptoms such as fatigue, shortness of breath, difficulty breathing, joint and muscle aches, and the like. The two-component combination drug product comprises effective amounts of ANTABUSE (disulfiram) and PURINETHOL (mercaptopurine, 6-mercaptopurine, or 6-MP) or its prodrug IMURAN (azathioprine) or hydrates of these compounds. A three-component combination drug product adds, in addition to the foregoing active ingredients, an effective amount of dexamethasone or pharmacologically acceptable salts thereof. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 25. Jan. |
| 773 | 1 | 8 | |g year:2024 |g day:25 |g month:01 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/89578094/publication/US2024024329A1?q=US2024024329 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 25 |c 01 | ||